NeuroMetrix (NASDAQ:NURO) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Down 2.2 %

Shares of NURO stock opened at $3.93 on Wednesday. The company has a market capitalization of $8.02 million, a P/E ratio of -0.86 and a beta of 2.20. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73. The firm has a 50-day moving average price of $4.00 and a 200 day moving average price of $3.87.

NeuroMetrix (NASDAQ:NURO) last announced its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The business had revenue of $0.59 million during the quarter. During the same quarter in the prior year, the firm earned ($1.66) earnings per share.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.